Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report), Cellectis SA (CLLS – Research Report) and Orthofix (OFIX – Research Report).
Iovance Biotherapeutics (IOVA)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Iovance Biotherapeutics today and set a price target of $25.00. The company’s shares closed last Friday at $12.18.
According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Iovance Biotherapeutics is a Strong Buy with an average price target of $24.40, representing an 114.6% upside. In a report issued on August 4, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
Cellectis SA (CLLS)
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Cellectis SA today and set a price target of $11.00. The company’s shares closed last Friday at $3.46, close to its 52-week low of $2.30.
According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of
Cellectis SA has an analyst consensus of Moderate Buy, with a price target consensus of $7.50, a 134.4% upside from current levels. In a report issued on August 1, Robert W. Baird also maintained a Buy rating on the stock with a $10.00 price target.
Orthofix (OFIX)
JMP Securities analyst David Turkaly reiterated a Hold rating on Orthofix today. The company’s shares closed last Friday at $22.77, close to its 52-week low of $22.66.
According to TipRanks.com, Turkaly is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Orthofix with a $31.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOVA:
- JMP Securities Sticks to Its Hold Rating for NextCure (NXTC)
- JMP Securities Sticks to Their Buy Rating for Generation Bio (GBIO)
- Positive Report for OZ Minerals Limited (OZMLF) from Ord Minnett
- Rosenblatt Securities Sticks to Its Buy Rating for IMAX (IMAX)
- Cowen & Co. Remains a Buy on Westinghouse Air Brake Technologies (WAB)